Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [4150]

Xaluritamig plus abiraterone shows promising anti-tumour activity with...

Dr David Pook - Monash Health, Melbourne, Australia

Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC ( Dr David Pook - Monash Health, Melbourne, Australia )

Tarlatamab improves brain metastases control and survival compared to chemo in...

Dr Giannis Mountzios - The University of Athens, Athens, Greece

Tarlatamab improves brain metastases control and survival compared to chemo in SCLC ( Dr Giannis Mountzios - The University of Athens, Athens, Greece )

miR371 shows promise as a surveillance biomarker for relapse in early-stage...

Dr Lucia Nappi - University of British Columbia, Vancouver, Canada

miR371 shows promise as a surveillance biomarker for relapse in early-stage germ cell tumours ( Dr Lucia Nappi - University of British Columbia, Vancouver, Canada )

Implanted tile-based radiation shows promise compared with stereotactic...

Dr Jeffrey Weinberg - MD Anderson Cancer Center, Houston, USA

Implanted tile-based radiation shows promise compared with stereotactic radiotherapy for brain metastases ( Dr Jeffrey Weinberg - MD Anderson Cancer Center, Houston, USA )

Lorlatinib delivers 7-year progression-free survival and durable brain control...

Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong

Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC ( Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong )

Low-dose pembrolizumab plus chemotherapy improves survival and expands access...

Dr Nandini Menon - Tata Memorial Centre, Mumbai, India

Low-dose pembrolizumab plus chemotherapy improves survival and expands access in advanced NSCLC ( Dr Nandini Menon - Tata Memorial Centre, Mumbai, India )

ASCO 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke

ASCO 2026: Latest updates in mRCC ( Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke )

Adagloxad simolenin plus OBI-821 shows no survival benefit compared to standard...

Dr Hope Rugo - City of Hope, Duarte, USA

Adagloxad simolenin plus OBI-821 shows no survival benefit compared to standard of care in triple-negative breast cancer ( Dr Hope Rugo - City of Hope, Duarte, USA )

ASCO 2026: Breast cancer overview

Dr Hope Rugo - City of Hope, Duarte, USA

ASCO 2026: Breast cancer overview ( Dr Hope Rugo - City of Hope, Duarte, USA )

mRNA-4359 plus pembrolizumab shows high response rates and robust T-cell...

Dr Pavlina Spiliopoulou - Beatson West of Scotland Cancer Centre, Glasgow, UK

mRNA-4359 plus pembrolizumab shows high response rates and robust T-cell activation in melanoma ( Dr Pavlina Spiliopoulou - Beatson West of Scotland Cancer Centre, Glasgow, UK )

Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in...

Dr Daniel Portik - European Organisation for Research and Treatment of Cancer...

Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management? ( Dr Daniel Portik - European Organisation for Research and Treatment of Cancer, Brussels, Belgium )

Part 1: Why test?

Dr Elena Castro - Hospital Universitario 12 de Octubre, Madrid, Spain

Part 1: Why test? ( Dr Elena Castro - Hospital Universitario 12 de Octubre, Madrid, Spain )

More from ecancer